Compare STRA & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STRA | GENB |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 1996 | 2026 |
| Metric | STRA | GENB |
|---|---|---|
| Price | $81.05 | $15.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $87.00 | $23.20 |
| AVG Volume (30 Days) | 316.0K | ★ 484.7K |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.04% | N/A |
| EPS Growth | ★ 15.85 | N/A |
| EPS | ★ 3.19 | N/A |
| Revenue | ★ $997,137,000.00 | N/A |
| Revenue This Year | $4.71 | N/A |
| Revenue Next Year | $4.67 | $16.58 |
| P/E Ratio | $25.08 | ★ N/A |
| Revenue Growth | ★ 57.23 | N/A |
| 52 Week Low | $69.70 | $11.00 |
| 52 Week High | $89.73 | $18.18 |
| Indicator | STRA | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 49.94 | 56.24 |
| Support Level | $74.47 | $11.82 |
| Resistance Level | $84.77 | $15.05 |
| Average True Range (ATR) | 3.58 | 0.80 |
| MACD | -0.24 | 0.15 |
| Stochastic Oscillator | 34.90 | 88.46 |
Strategic Education Inc. is an education services company that provides access to high-quality education through campus-based and online post-secondary education offerings, as well as through programs to develop job-ready skills for high-demand markets. The company operates through wholly-owned subsidiaries Strayer University and Capella University, both accredited post-secondary institutions of higher education located in the United States, as well as Torrens University, an accredited post-secondary institution of higher education located in Australia. It provide employees with access to affordable and industry relevant training, certificate, and degree programs. The reportable segments of the company are U.S. Higher Education, Australia/New Zealand and Education Technology Services.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.